{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:44:25Z","timestamp":1785156265276,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2709,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,2,5]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Oral and topical mesalazine formulations are effective in active ulcerative colitis, but little is known on the efficacy of combined treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To compare the efficacy of oral mesalazine vs. combined oral and topical mesalazine in mildly to moderately active ulcerative colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with mildly to moderately active ulcerative colitis (Clinical Activity Index, CAI 4\u201312) were identified at 15 participating centres. They were randomized to receive either mesalazine 4\u2003g orally plus placebo enema, or mesalazine 2\u2003g orally plus mesalazine 2\u2003g rectally as a liquid enema for 6\u2003weeks. The rate of clinical remission (CAI\u2003&lt;\u20034) or clinical remission\/improvement (reduction of CAI of 50% from baseline) at 6\u2003weeks and time to clinical remission\/improvement were primary end\u2010points; the rate of endoscopic remission was a secondary end\u2010point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>67 patients were assigned to oral treatment and 63 to combined treatment. One patient in the oral group and 2 in the combined group discontinued the treatment due to adverse events. Following an intention\u2010to\u2010treat analysis, the rate of clinical remission was 82% for oral treatment and 87% for combined treatment (<jats:italic>P<\/jats:italic>=0.56); the mean time to remission 22.2 and 20.2\u2003days, respectively (<jats:italic>P<\/jats:italic>=0.29); the rate of clinical remission\/improvement and the rate of endoscopic remission were 85% and 91% (<jats:italic>P<\/jats:italic>=0.503) and 58% and 71% (<jats:italic>P<\/jats:italic>=0.21), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In patients with mild active ulcerative colitis, mesalazine 4\u2003g orally and 2\u2003g orally plus 2\u2003g enema are equally effective in inducing disease remission.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.00913.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:42Z","timestamp":1047354222000},"page":"251-256","source":"Crossref","is-referenced-by-count":69,"title":["Oral versus combination mesalazine therapy in active ulcerative colitis: a double\u2010blind, double\u2010dummy, randomized multicentre study"],"prefix":"10.1111","volume":"15","author":[{"given":"M.","family":"Vecchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Meucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beltrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Di Maurizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ganio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Usai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fornaciari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Franchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.5.669"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-350"},{"key":"e_1_2_6_6_2","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial","volume":"88","author":"Hanauer SB","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00009"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90523-7"},{"key":"e_1_2_6_9_2","first-page":"412","article-title":"5\u2010aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial","volume":"81","author":"Friedman LS","year":"1986","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90621-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.8.929"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.5.676"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780040202"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00384.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5\u2010aminosalycilic acid enemas: effective agent in maintaining remission in left\u2010sided ulcerative colitis","volume":"95","author":"Biddle W","year":"1988","journal-title":"Gastroenterology"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.2.195"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.228_a.x"},{"key":"e_1_2_6_18_2","first-page":"505","article-title":"Comparison of the efficacy and safety of sulphasalaziene and mesalazines in the maintenance treatment of ulcerative colitis: a meta\u2010analysis","volume":"5","author":"De Franchis R","year":"1993","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957030-00013"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02236902"},{"key":"e_1_2_6_21_2","first-page":"1867","article-title":"A double\u2010blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi M","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_22_2","first-page":"1143","article-title":"Combined therapy with 5\u2010Aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis; a randomized double\u2010blind study","volume":"92","author":"D\u2019Albasio G","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780050113"},{"key":"e_1_2_6_24_2","first-page":"229","article-title":"Oral delayed\u2010release mesalazine in the treatment of mild ulcerative colitis: a dose\u2010ranging study","volume":"2","author":"Miglioli M","year":"1990","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00913.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00913.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00913.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:34:07Z","timestamp":1697506447000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00913.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,5]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2,5]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00913.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00913.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,5]]}}}